Section Arrow
Quote
VTRS.NASDAQ
- Viatris
Quotes are at least 15-min delayed:2025/05/10 04:37 EDT
Last
 8.77
-0.32 (-3.52%)
Day High 
9.315 
Prev. Close
9.09 
1-M High
9.575 
Volume 
19.14M 
Bid
8.78
Ask
8.84
Day Low
8.745 
Open
9.015 
1-M Low
6.85 
Market Cap 
10.78B 
Currency USD 
P/E 227.2 
%Yield 6.84 
10-SMA 8.5 
20-SMA 8.05 
50-SMA 8.59 
52-W High 13.55 
52-W Low 6.85 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.53/2.41
Enterprise Value
25.00B
Balance Sheet
Book Value Per Share
15.71
Cash Flow
Cash Flow Yield
0.21
Income Statement
Total Revenue
14.74B
Operating Revenue Per Share
13.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
SHPHShuttle Pharmaceuticals Holdings Inc0.2325-0.0375-13.89%-- 
PTPIPetros Pharmaceuticals Inc0.1201-0.0053-4.23%-- 
VTRSViatris8.77-0.32-3.52%227.2PE
TEVATeva Pharmaceutical Industries Limited16.93-1.14-6.31%-- 
IXHLIncannex Healthcare0.1135+0.0009+0.80%-- 
Quotes are at least 15-min delayed：2025/05/10 04:37 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.